Nexium Buyers Win Class Cert In AstraZeneca Antitrust MDL

Law360, Los Angeles (November 14, 2013, 9:51 PM ET) -- A Massachusetts federal judge certified a class of Nexium end-buyers on Thursday who accused AstraZeneca PLC and others of violating antitrust laws by delaying a generic version of AstraZeneca’s heartburn drug, ruling the class met adequacy and predominance requirements.

In the multidistrict litigation, the judge certified a damages class consisting of an unidentified number of individual consumers, third-party payors, union plan sponsors and insurance companies that bought or provided reimbursements for Nexium in more than 20 states and the District of Columbia. The class period will...
To view the full article, register now.